{
    "symbol": "IPA",
    "quarter": 3,
    "year": 2022,
    "date": "2022-03-16 14:56:08",
    "content": " Lastly, within our revenue discussion, our product catalog sales increased this quarter by $400,000 compared to the same period last year, adding to our year-to-date cumulative catalog sales of $1.2 million, an increase of about 58% compared to the same period last year. The company's total revenues of 4.8 million during the three months ended January 31, 2022, compared to 4.5 million in 2021, 300,000, or 6.6% increase. Most notably, the company's project revenue was 4.1 million, compared to 3.3 million the same period last year a 22.6% increase. The higher product sales during the three months ended January 31, 2021, related to the company's first sale of its internally generated therapeutic antibody asset. Research expense increased 1.8 million from nil in 2021 due to the company's undertaking a strategic investment in research including the company's SARS-CoV-2 PolyTope cocktail, and other research projects that Jennifer mentioned that can be found on Talem's website. This increase includes the addition of the strategic leadership roles most recently, the VP of Marketing and VP of client relations to support the company's organic growth and routine pay increases and the addition of directors cash compensation that was effective after the fiscal year 2020 annual general meeting held in November. So in summary for the financials, highlights for the quarter included the company earned 4.8 million in total revenue, a 6.6% increase over the same period last year, the company's project revenue made up 4.1 million of that increase, a total of 22.6% increase over the same period last year. On a year-to-date basis, the company achieved revenues of 14.1 million during the nine months ended January 31, 2022, compared to 13 million in 2021, a 1.2 million or 8.4% increase. The company's project revenue was 12.7 million, compared to 11.3 million the same period last year, 11.7% increase. Product sales during the nine months ended January 31, 2022 included -- totaled 1.2 million a decrease of 523,000 compared to the same period last year. The lower product sales during the nine months ended January 31, 2022 relates to the company's sale of its first internally generated therapeutic antibody during fiscal year 2021. In fiscal year 2022, the company achieved product catalog sales of 1.2 million during this nine month period, as compared to 500,000 for the same period last year as mentioned during the quarterly update. The company's operating expenses year-to-date were 20.1 million, compared to 13.3 million in 2021, an increase of 6.9 million. Research expense increased to 5.8 million from 1.1 million in 2021 due to the company's undertaking of strategic investments in research, including the company's SARS-CoV-2 PolyTope cocktail and other research projects, most of which can be found on Talem's website. The company's insurance cost increased to 1.5 million as compared to 301,000 during the same period last year. The company recorded a net loss of 12.1 million year-to-date compared to a net loss of 2.3 million for the nine months ended January 31, 2021. The 9.8 million increased net loss can be summarized primarily as a result of lower gross profit and the company's investment in research and development, increases in insurance and professional fees, higher salaries, and benefits to support our strategic plans and operations, and lower grant and subsidy income. For the nine months ended January 31, 2022, the company's adjusted EBITDA was a loss of 6.9 million, compared to a gain of 2.6 million in 2021, a decline of 9.5 million."
}